Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus EMEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus EMEND.
CLOPRA-"YELLOW" vs EMEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic